Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Why Mounjaro Causes Injection Site Reactions: The Mechanism Explained

By
Published Updated Last reviewed
2 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • What it is / A reaction at the Mounjaro injection site
  • How common (Mounjaro label) / 3.2% on Mounjaro vs 0.4% on placebo in the adult placebo-controlled pool [2]
  • Documented immune finding / Treatment-emergent anti-tirzepatide antibodies in 51.1% of 5,025 patients with type 2 diabetes across seven phase 3 trials [1]
  • Antibody link / 4.6% of antibody-positive vs 0.7% of antibody-negative adults had injection site reactions [2]
  • Course in the data / Most hypersensitivity and injection site reactions were nonserious and nonsevere, and most occurred or resolved irrespective of antibody status or titer [1]
  • Serious hypersensitivity / Anaphylaxis and angioedema have been reported; the label says to discontinue if suspected and promptly seek medical advice [2]
  • Label injection sites / The abdomen and thigh, or the back of the upper arm when another person gives the injection; rotate sites with each dose [2]

What is an injection site reaction with Mounjaro?

Mounjaro is given once weekly by subcutaneous injection [2]. The label reports injection site reactions in 3.2% of Mounjaro-treated adults versus 0.4% of placebo-treated adults in its pool of placebo-controlled trials [2]. It lists the abdomen and thigh as injection sites, or the back of the upper arm when another person gives the injection, and instructs users to rotate injection sites with each dose [2].

Does an immune response explain the reactions?

Tirzepatide can trigger an anti-drug antibody response. In an analysis of seven phase 3 trials, treatment-emergent anti-tirzepatide antibodies developed in 51.1% of 5,025 patients with type 2 diabetes [1]. More antibody-positive patients experienced injection site reactions or hypersensitivity reactions than antibody-negative patients [1]. The label gives injection site reactions in 119 of 2,570 antibody-positive adults (4.6%) versus 18 of 2,455 antibody-negative adults (0.7%) [2].

Antibodies were linked to more injection site reactions, but most reactions occurred or resolved regardless of antibody status or titer [1]. Antibody status, titer, and neutralizing antibody status had no effect on tirzepatide pharmacokinetics or efficacy [1].

What the label says about serious reactions

The Mounjaro label lists serious hypersensitivity reactions, including anaphylaxis and angioedema, as a warning [2]. It says to discontinue Mounjaro if a hypersensitivity reaction is suspected and promptly seek medical advice [2]. Mounjaro is contraindicated in patients with known serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro [2]. The label lists injection site reactions and hypersensitivity reactions as separate adverse reactions [2].

Frequently asked questions

What is the main drug-specific finding?
The clearest finding is an immune association: treatment-emergent anti-tirzepatide antibodies developed in 51.1% of 5,025 patients, and more antibody-positive patients had injection site or hypersensitivity reactions, though most were nonserious and nonsevere [1].
Are injection site reactions a sign of a serious allergy?
The label lists injection site reactions and hypersensitivity reactions as separate adverse reactions. It names anaphylaxis and angioedema as serious hypersensitivity reactions and says to discontinue Mounjaro if one is suspected [2].
Do anti-tirzepatide antibodies make Mounjaro stop working?
In the seven-trial antibody analysis, antibody status, titer, and neutralizing antibody status had no effect on tirzepatide pharmacokinetics or efficacy [1].
Where does the label say to inject Mounjaro?
The label lists the abdomen and thigh, or the back of the upper arm when another person gives the injection, and instructs users to rotate injection sites with each dose [2].
How common are injection site reactions in the Mounjaro label?
In the label's adult placebo-controlled pool, injection site reactions were reported in 3.2% of Mounjaro-treated patients and 0.4% of placebo-treated patients. They are not in the table of common adverse reactions reported in at least 5% of patients [2].

References

  1. Mullins GR, Hodsdon ME, Li YG, Anglin G, Urva S, Schneck K, et al. Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies. J Clin Endocrinol Metab. 2024;109(2):361-369. Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies
  2. U.S. National Library of Medicine, DailyMed. Mounjaro injection and KwikPen (tirzepatide) prescribing information. Mounjaro injection and KwikPen (tirzepatide) label
Evidence overview for Why Mounjaro Causes Injection Site Reactions: The Mechanism Explained